Short report: Characterizing HIV care among a clinical sample of transgender women living with HIV. Issue 4 (22nd February 2022)

• Record Type: Journal Article
• Authors: Lacombe‐Duncan, Ashley; Shokoohi, Mostafa; Persad, Yasmeen; Underhill, Angela; Machouf, Nima; Côté, Pierre; Wheatley, Megan; Gupta, Meenakshi; Kyne, Luke T.; Besharati, Amir A.; Fung, Raymond; Chan, L. Y. Louie; Arbess, Gordon; Bourns, Amy; Nguyen, Quang; Loutfy, Mona
• Other Names: Gilleece Yvonne guestEditor.
• Is Part Of: HIV medicine. Volume 23:Issue 4(2022)
• Page Start: 324
• Page End: 330
• Publication Date: 2022-02-22
• Subjects: antiretroviral therapy -- gender affirmation -- HIV care cascade -- transfeminine -- transgender women -- viral suppression; HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.13261
• Languages: English
• ISSNs: 1464-2662

Abstract

Abstract: Introduction: This study aimed to characterize and identify factors associated with HIV care among transgender (trans) women living with HIV (TWLWH) in two urban centres in Canada. Methods: Retrospective data were collected from clinic charts of TWLWH aged 16 years and older across seven family medicine, endocrinology and/or HIV clinics in Montreal and Toronto, Canada, from 2018 to 2019 ( n = 86). We assessed the proportion of individuals being ever engaged in HIV care [defined as having any recorded antiretroviral therapy (ART) regimen and/or viral load], current ART use, and most recent viral load (suppressed [<200 copies/ml] vs. unsuppressed) overall and compared across subgroups using χ 2 tests. Results: All TWLWH in our sample [100.0%, 95% confidence interval (CI): 95.8–100.0%] were engaged in HIV care; most (93.0%, 95% CI: 85.4–97.4%) were currently using ART and most (93.4%, 95% CI: 85.3–97.8%) with complete data ( n = 71/76) were virally suppressed. A higher proportion of trans women of colour (100.0%) reported current ART use compared with white trans women (76.9%, p = 0.017). A higher proportion of those with no documented history of injection drug use (IDU; 96.6%) were virally suppressed compared with those with a history of IDU (66.7%, p = 0.022). Although not statistically significant, 96.2% of those currently reporting feminizing hormone use were virally suppressed, compared with 85.0% of those not reporting use ( p = 0.202). Conclusions: Once engaged in HIV care, TWLWH in Canada appear to have excellent ART use and viral suppression. Findings can be leveraged to identify target populations to enhance HIV care and to further explore the relationship between gender‐affirming medical care and HIV care.